Related Experiment Video
Updated: Mar 29, 2026
05:31
Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
3.5K
Recent advances in transcatheter pulmonary valve delivery
1St Joseph's Children's Hospital, Tampa, Florida, USA.
Current Opinion in Cardiology
|November 25, 2015
Summary
Transcatheter pulmonary valve replacement (TPVR) is increasingly used for congenital heart disease, expanding knowledge of its benefits and limitations. Ongoing research clarifies procedural limits and rare late adverse events like infective endocarditis.
Area of Science:
- Cardiology
- Interventional Cardiology
- Congenital Heart Disease
Background:
- Transcatheter pulmonary valve replacement (TPVR) is a relatively new procedure for congenital heart disease.
- Expanded use has increased familiarity and knowledge of its applications.
Purpose of the Study:
- To review the expanded use and understanding of transcatheter pulmonary valve implantation (TPVI).
- To define the procedural limits and uncommon late adverse events associated with TPVI.
Main Methods:
- Review of expanded worldwide use and longer-term outcomes of TPVI.
- Analysis of procedural limitations and late adverse events, including infective endocarditis.
Main Results:
- TPVI is being adapted for various clinical scenarios beyond its initial US approval.
- Coronary compression is a recognized technical limitation.
- Infective endocarditis is an uncommon but significant late adverse event.
Conclusions:
- Wider application of TPVI has improved understanding of patient selection.
- Current procedural limits and important late issues are better defined.
- Further research is needed to fully understand long-term outcomes.
